• Je něco špatně v tomto záznamu ?

Perioperative platform for muscle-invasive bladder cancer trials: designs and endpoints

E. Laukhtina, M. Moschini, JY. Teoh, SF. Shariat

. 2025 ; 35 (1) : 35-40. [pub] 20240911

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002930

PURPOSE OF REVIEW: This review explores the design and endpoints of perioperative platforms in clinical trials for muscle-invasive bladder cancer (MIBC). RECENT FINDINGS: The choice of clinical trial design in perioperative platforms for MIBC must align with specific research objectives to ensure robust and meaningful outcomes. Novel designs in perioperative platforms for MIBC integrate bladder-sparing approaches. Primary endpoints such as pathological complete response and disease-free survival are highlighted for their role in expediting trial results in perioperative setting. Incorporating patient-reported outcomes is important to inform healthcare decision makers about the outcomes most meaningful to patients. Given the growing body of evidence, potential biomarkers, predictive and prognostic tools should be considered and implemented when designing trials in perioperative platforms for MIBC. SUMMARY: Effective perioperative platforms for MIBC trials are critical in enhancing patient outcomes. The careful selection and standardization of study designs and endpoints in the perioperative platform are essential for the successful implementation of new therapies and the advancement of personalized treatment approaches in MIBC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002930
003      
CZ-PrNML
005      
20250206103945.0
007      
ta
008      
250121s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001228 $2 doi
035    __
$a (PubMed)39262345
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
245    10
$a Perioperative platform for muscle-invasive bladder cancer trials: designs and endpoints / $c E. Laukhtina, M. Moschini, JY. Teoh, SF. Shariat
520    9_
$a PURPOSE OF REVIEW: This review explores the design and endpoints of perioperative platforms in clinical trials for muscle-invasive bladder cancer (MIBC). RECENT FINDINGS: The choice of clinical trial design in perioperative platforms for MIBC must align with specific research objectives to ensure robust and meaningful outcomes. Novel designs in perioperative platforms for MIBC integrate bladder-sparing approaches. Primary endpoints such as pathological complete response and disease-free survival are highlighted for their role in expediting trial results in perioperative setting. Incorporating patient-reported outcomes is important to inform healthcare decision makers about the outcomes most meaningful to patients. Given the growing body of evidence, potential biomarkers, predictive and prognostic tools should be considered and implemented when designing trials in perioperative platforms for MIBC. SUMMARY: Effective perioperative platforms for MIBC trials are critical in enhancing patient outcomes. The careful selection and standardization of study designs and endpoints in the perioperative platform are essential for the successful implementation of new therapies and the advancement of personalized treatment approaches in MIBC.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x chirurgie $x patologie $x terapie $x mortalita $7 D001749
650    12
$a invazivní růst nádoru $7 D009361
650    _2
$a výzkumný projekt $7 D012107
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a stanovení cílového parametru $7 D023381
650    _2
$a cystektomie $x metody $x škodlivé účinky $7 D015653
650    _2
$a výsledek terapie $7 D016896
650    _2
$a perioperační péče $x metody $x normy $7 D019990
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Moschini, Marco $u Department of Urology, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Teoh, Jeremy Yuen-Chun $u S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 35, č. 1 (2025), s. 35-40
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39262345 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103940 $b ABA008
999    __
$a ok $b bmc $g 2262991 $s 1238937
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 35 $c 1 $d 35-40 $e 20240911 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace